glp 1 for cardiovascular health Comprehensive Overview of GLP-1 RAs in Cardiometabolic Care GLP-1 Injections for Medical Weight

According to statistics mentioned by Zealand, although two approved once-weekly GLP-1 receptor agonists (semaglutide and tirzepatide) have been authorized for treating obesity and can achieve a weight reduction of approximately 15-21%, up to 30% of obese patients discontinue the treatment within the first month of starting a GLP-1 receptor agonist (GLP-1RA) therapy

However, one leading hypothesis is that the rapid correction of hyperglycemia induced by these drugs may play a role

Muscle Fiber Regeneration: BPC-157 increases satellite cell activity, which rebuilds damaged muscle fibers

February 18th, 2024: Ozempic Lawsuits Surge as Illinois Woman Suffers Torn Esophagus, Week-Long Hospitalization Lawsuits against the makers of Ozempic and other similar drugs are growing, and the highly popularized medication is continuing to make news headlines for the wrong reasons